Article
Oncology
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
Summary: This prospective trial examined the safety of COVID-19 vaccines in patients with thoracic cancer receiving anticancer treatments. The results showed no safety concerns and a low rate of vaccine-related adverse events. The study supports prioritizing vaccination for lung cancer patients undergoing active treatment.
CLINICAL LUNG CANCER
(2023)
Article
Biochemistry & Molecular Biology
Dalil Hannani, Estelle Leplus, David Laurin, Benjamin Caulier, Caroline Aspord, Natacha Madelon, Ekaterina Bourova-Flin, Christian Brambilla, Elisabeth Brambilla, Anne-Claire Toffart, Karine Laulagnier, Laurence Chaperot, Joel Plumas
Summary: The purpose of ICI-based therapies is to help the patient's immune system combat tumors. Therapeutic vaccines with dendritic cells have not shown significant benefit, so a new vaccine based on an allogeneic dendritic cell line has been developed. This new vaccine demonstrates efficient activation of specific T cells and the synergistic effect of anti-PD-1 antibodies, showing potential for NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nanoscience & Nanotechnology
Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Edward Cheah, Benjamin Thierry
Summary: This study investigates the biodistribution of intratumorally administered aPD-1 nanoformulation and finds that it has lower off-target organ distribution and higher accumulation in tumors and tumor draining lymph nodes compared to free antibodies. In vitro studies also show that aPD-1 nanoformulation effectively inhibits PD-1 expression on T-cells and enhances their cytotoxicity against head and neck cancer cells. Further research is needed to assess the potential of intratumoral administration of aPD-1 nanoformulation in reducing toxicity and improving the tumor efficacy of immune checkpoint inhibitors.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Oncology
Li Pang, Mei Xie, Xidong Ma, Aiben Huang, Jialin Song, Jie Yao, Hui Deng, Duchao Zhang, Xuelei Zang, Fangping Ren, Jie Gao, Chongchong Wu, Yuanyong Wang, Xin Zhang, Xinyu Bao, Lei Pan, Xinying Xue
Summary: This study retrospectively analyzed the clinical and imaging data of 704 patients with non-small cell lung cancer who received immunotherapy, and summarized the clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis.
Review
Biochemistry & Molecular Biology
Areti Strati, Panagiota Economopoulou, Evi Lianidou, Amanda Psyrri
Summary: The approval of monoclonal antibodies against PD-L1 and PD1 has revolutionized cancer treatment, but the occurrence of irAEs highlights the need for biomarker analysis with strong predictive value. Liquid biopsy is an important tool for clinical oncologists to monitor and adjust therapy, and CTCs expressing PD-L1 can serve as a clinically useful and non-invasive method to assess PD-L1 status in real-time.
Article
Immunology
Arnold S. Monto, Adam S. Lauring, Emily T. Martin
Summary: With waning immunity and the emergence of new variants, booster inoculations are necessary for the SARS-CoV-2 vaccine. The process is becoming similar to annual influenza vaccine updates, especially with the selection of BA.4/BA.5 as the Omicron strain for the updated COVID-19 vaccines. If COVID-19 develops seasonality, SARS-CoV-2 vaccines may only require annual review for updates, with booster recommendations based on conditions at that time.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Medicine, Research & Experimental
Elina Khatoon, Dey Parama, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Summary: Ovarian cancer is a deadly gynecological cancer with a low survival rate. Recent advancements in immunotherapy, particularly targeting the PD-1/PD-L1 axis, have shown promise in enhancing anti-tumor activity. Combinatorial treatment with small molecule inhibitors has also shown improved efficacy.
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Sebastian Wurster, Nathaniel D. Albert, Uddalak Bharadwaj, Moses M. Kasembeli, Jeffrey J. Tarrand, Naval Daver, Dimitrios P. Kontoyiannis
Summary: ICIs have potential in treating mucormycosis, but their mechanism of action remains unclear. This study investigated the effects of PD-1 and PD-L1 inhibitors on IPM in immunosuppressed mice. The results showed that ICI treatment improved clinical outcomes of IPM in mice, with PD-L1 inhibition yielding more favorable immune responses and sustained protection. However, further research is needed to determine the optimal dosage.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Virology
Ashley Moreland, Christina Gillezeau, Naomi Alpert, Emanuela Taioli
Summary: Vaccination campaigns targeting influenza are effective in reaching those most vulnerable to serious COVID-19, and if implemented, may help reach more vulnerable individuals who have not yet been vaccinated against COVID-19.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Oncology
Mark Dapash, Brandyn Castro, David Hou, Catalina Lee-Chang
Summary: This review discusses various immunotherapeutic strategies currently being investigated in the treatment of glioblastoma, including checkpoint inhibitors, vaccination strategies, and CAR T-cell therapy. However, due to the low immunogenicity of the tumor, treatment outcomes remain suboptimal.
Review
Biochemistry & Molecular Biology
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
Summary: Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Article
Chemistry, Medicinal
Alessandra Riccio, Alice Coletti, Daniela Dolciami, Andrea Mammoli, Bruno Cerra, Sonia Moretti, Antimo Gioiello, Simone Ferlin, Efisio Puxeddu, Antonio Macchiarulo
Summary: Interaction between PD-1 and PD-L1 in the tumor microenvironment leads to T-cell inactivation, promoting immune escape. Monoclonal antibodies targeting PD-1/PD-L1 have shown clinical success, but limitations such as drug resistance and narrow therapeutic response rate necessitate the development of more efficacious small molecule-based immunotherapies.
Article
Oncology
Kyle Hansen, Sandeep Kumar, Kathryn Logronio, Sarah Whelan, Samir Qurashi, Hsin-Yuan Cheng, Andrew Drake, Margaret Tang, Patrick Wall, David Bernados, Ling Leung, Eran Ophir, Zoya Alteber, Gady Cojocaru, Moran Galperin, Masha Frenkel, Mark White, John Hunter, Spencer C. Liang, Maya F. Kotturi
Summary: TIGIT and its cognate ligand PVR are widely expressed in human cancers, and the antibody COM902 targeting TIGIT shows potential in enhancing anti-tumor immune responses both in-vitro and in-vivo, making it a promising candidate for the treatment of advanced malignancies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Medicine, Research & Experimental
Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi, Sebastiano Buti, Marco Tucci, Alessandro Russo, Maria Chiara Sergi, Vincenzo Adamo, Luigia S. Stucci, Melissa Bersanelli, Giulia Mazzaschi, Francesco Spagnolo, Francesca Rastelli, Francesca Chiara Giorgi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Laura Pala, Paola Queirolo, Sergio Bracarda, Serena Macrini, Stefania Gori, Alessandro Inno, Federica Zoratto, Enrica T. Tanda, Domenico Mallardo, Maria Grazia Vitale, Thomas Talbot, Paolo A. Ascierto, David J. Pinato, Corrado Ficorella, Giampiero Porzio, Alessio Cortellini
Summary: The study in Italy showed a trend of increasing prescription of ICIs in frail patients during late stages of life. Patients who received ICIs within 30 days of death had higher proportions of patients with ECOG-PS >= 2 and a higher burden of disease. It is important to exercise caution when evaluating ICI treatment for patients with poor PS and high disease burden.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Sebastiano Buti, Chiara Tommasi, Giulia Scartabellati, Ugo De Giorgi, Nicole Brighi, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Massimo de Filippo, Alessio Cortellini, Melissa Bersanelli
Summary: Tyrosine kinase inhibitors (TKIs) are crucial for treating metastatic renal cell carcinoma (mRCC). However, the concurrent use of TKIs with proton-pump inhibitors (PPIs) can have adverse effects on treatment outcomes. A retrospective study in Italy found that the concurrent use of PPIs significantly reduced progression-free survival (PFS) and overall survival (OS) in mRCC patients treated with pazopanib or cabozantinib. Furthermore, PPI use also impacted treatment toxicity and compliance. Therefore, the indiscriminate use of PPIs should be avoided and patients requiring gastroprotective therapy should be carefully selected.
Article
Biochemistry & Molecular Biology
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Summary: The study aimed to investigate the effectiveness and tolerability of pembrolizumab-axitinib combination as a first-line treatment option for patients with chromophobe and papillary metastatic renal cell carcinoma (mRCC). The results showed that this combination therapy had a good response rate and tolerability in patients with chromophobe and papillary mRCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Sebastiano Buti, Umberto Basso, Diana Giannarelli, Ugo De Giorgi, Marco Maruzzo, Roberto Iacovelli, Luca Galli, Camillo Porta, Francesco Carrozza, Giuseppe Procopio, Giuseppe Fonarini, Giovanni Lo Re, Matteo Santoni, Roberto Sabbatini, Antonio Cusmai, Paolo Andrea Zucali, Carlo Aschele, Editta Baldini, Elena Zafarana, Adolfo Favaretto, Silvana Leo, Alketa Hamzaj, Rosanna Mirabelli, Franco Nole', Silvia Zai, Claudio Chini, Cristina Masini, Sonia Fatigoni, Andrea Rocchi, Emiliano Tamburini, Alessio Cortellini, Melissa Bersanelli
Summary: We developed a drug-based score to predict prognosis and treatment response in advanced cancer patients receiving immune checkpoint inhibitors (ICIs), and validated its value in a population of metastatic renal cell carcinoma patients treated with ipilimumab plus nivolumab. The model considers the use of certain drugs before immunotherapy initiation and demonstrated significant and clinically meaningful predictions for overall survival and progression-free survival. Further development will involve analyzing the gut microbiome and its link to drug exposure and immune sensitivity.
JOURNAL OF IMMUNOTHERAPY
(2023)
Article
Oncology
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica T. Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato
Summary: The impact of type 2 diabetes mellitus (T2DM) on the clinical outcome of immune checkpoint inhibitors (ICI) in solid tumor patients is uncertain. Patients on glucose-lowering medications (GLM) for T2DM had worse overall survival (OS) and progression-free survival (PFS) independent of the number of GLM received. Among the GLM, metformin use was associated with increased risk of death and disease progression/death. Further studies are needed to understand the relative impact of metformin and preexisting T2DM diagnosis on outcomes in this population.
CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Satoru Taguchi, Taketo Kawai, Sebastiano Buti, Melissa Bersanelli, Yukari Uemura, Kenjiro Kishitani, Jimpei Miyakawa, Kazuma Sugimoto, Yu Nakamura, Fusako Niimi, Tomoyuki Kaneko, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Tetsuya Fujimura, Hiroshi Fukuhara, Tohru Nakagawa, Satoru Takahashi, Haruki Kume
Summary: This study aimed to validate a "drug score" for assessing patients with urothelial carcinoma receiving immunotherapy. The results showed that the drug score classified patients into three risk groups with significantly different survivals. The score was validated in bladder cancer but not in upper-tract urothelial cancer.
Article
Medicine, General & Internal
Robert J. Motzer, Paul Russo, Viktor Gruenwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthelemy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albiges, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vazquez Estevez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
Summary: This is a phase 3 randomized trial evaluating the efficacy and safety of adjuvant nivolumab plus ipilimumab versus placebo in patients with resected localised renal cell carcinoma. The results showed that adjuvant therapy with nivolumab plus ipilimumab did not improve disease-free survival compared to placebo. This study does not support the use of this regimen as adjuvant treatment for renal cell carcinoma.
Review
Biotechnology & Applied Microbiology
Melissa Bersanelli, Sara Elena Rebuzzi, Giandomenico Roviello, Martina Catalano, Matteo Brunelli, Mimma Rizzo
Summary: For years, patients with non-conventional histologies of renal cell carcinoma (RCC) were excluded from prospective randomized clinical trials, leading to the use of the same treatment strategies as clear-cell RCC (ccRCC). However, recent reviews have found that immune checkpoint inhibitors (ICIs) show promising antitumor activity in non-clear cell (ncc)RCC. Single-agent ICIs have shown similar response rates to ccRCC, and combination strategies have shown robust results in sarcomatoid variants of RCC.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Oncology
Malvina Cremante, Silvia Puglisi, Annalice Gandini, Antonio Guadagno, Fabio Catalano, Alessandra Damassi, Veronica Murianni, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Sebastiano Buti, Sara Elena Rebuzzi, Pasquale Rescigno, Giuseppe Fornarini
Summary: Apalutamide, an oral selective androgen receptor inhibitor, is approved by FDA for the treatment of high-risk non-metastatic castration-resistant prostate cancer (M0 CRPC) and metastatic castration-sensitive prostate cancer (mHSPC). This case report describes a rare skin adverse event, lichenoid reaction, induced by Apalutamide. A multidisciplinary approach confirmed the correlation between lichenoid reaction and the drug.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Urology & Nephrology
Giuseppe Fornarini, Sara E. Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Cora N. Sternberg, Ugo de Giorgi, Umberto Basso, Marco Maruzzo, Patrizia Giannatempo, Marta Ponzano, Emilio F. Giunta, Fabio Catalano, Veronica MURiANNi, Alessandra DAMASSi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Miguel A. Llaja Obispo, Alessio Signori, Giuseppe L. Banna
Summary: A new immunotherapy prognostic model was developed in this study, which stratified patients with advanced urinary tract carcinoma into five risk groups based on clinical and laboratory factors. It provided robust predictive ability for prognosis and survival outcome, and could be quickly adopted in clinical practice to inform treatment decisions.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Oncology
Emilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, Ugo De Giorgi, Marco Maruzzo, Sara Elena Rebuzzi, Marika Cinausero, Lucia Fratino, Helga Lipari, Teresa Gamba, Davide Bimbatti, Arianna Dri, Paola Ermacora, Francesca Vignani, Umberto Basso, Sebastiano Buti, Annalice Gandini, Malvina Cremante, Giuseppe Fornarini, Pasquale Rescigno, Giuseppe Luigi Banna
Summary: This study aimed to assess the characteristics of caregivers and the impact of their presence or absence on the clinical outcomes of older mCRPC patients treated with ABI or ENZ. The research found a detrimental effect of caregivers in managing older mCRPC patients, especially those identified as frail by the geriatric G8 screening score. Further research is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo, Luca Galli, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Sara Merler, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Camillo Porta
Summary: The ARON-1 study collected real-world data on the use of immuno-combination therapies as first-line treatment for mRCC patients globally. The study showed that immuno-combination therapies are effective in the real-world context of mRCC, with longer survival observed in patients treated with IO + TKI combinations compared to IO + IO combinations in the intermediate/poor risk population.
Review
Oncology
Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, Luca Isella, Marco Stellato, Michela Roberto, Roberto Iacovelli
Summary: Despite substantial progress in the treatment of advanced UC, there still exist uncertainties regarding the optimal treatment sequence for novel agents and reliable predictive biomarkers to aid treatment selection. There is also a need for effective treatment options in patients unfit for platinum-based chemotherapy.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Medicine, General & Internal
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Fabiana Perrone, Marco Maruzzo, Ernesto Rossi, Chiara Casadei, Vincenzo Montesarchio, Francesco Grossi, Mimma Rizzo, Maria Grazia Travagliato Liboria, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Caterina Accettura, Saverio Cinieri, Andrea Camerini, Mariella Soraru, Paolo Andrea Zucali, Serena Ricciardi, Antonio Russo, Giorgia Negrini, Maria Chiara Banzi, Gaetano Lacidogna, Giuseppe Fornarini, Letizia Laera, Claudia Mucciarini, Matteo Santoni, Claudia Mosillo, Andrea Bonetti, Lucia Longo, Donata Sartori, Editta Baldini, Michele Guida, Mauro Iannopollo, Roberto Bordonaro, Maria Francesca Morelli, Pierosandro Tagliaferri, Massimiliano Spada, Anna Ceribelli, Rosa Rita Silva, Franco Nole, Giordano Beretta, Petros Giovanis, Daniele Santini, Stefano Luzi Fedeli, Oriano Nanni, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Alberto Clemente, Michele Tognetto, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Sebastiano Buti, Diana Giannarelli
Summary: The INVIDIa-2 study found that influenza vaccination has a positive impact on the outcomes of advanced cancer patients receiving immune checkpoint inhibitor therapy. The vaccination was associated with improved overall survival, progression-free survival, and disease-control rate. These findings support the recommendation of vaccination in cancer patients and suggest a potential synergy between antiviral and antitumor immunity. Rating: 8/10.
Review
Oncology
Giulia Mazzaschi, Giulia Claire Giudice, Matilde Coriano, Davide Campobasso, Fabiana Perrone, Michele Maffezzoli, Irene Testi, Luca Isella, Umberto Maestroni, Sebastiano Buti
Summary: Urothelial carcinoma (UC) is the most common malignancy of the urinary tract, with bladder cancer (BC) accounting for 90% and urinary tract UC (UTUC) accounting for 5-10%. BC and UTUC have distinct features and profiles, leading to different clinical outcomes. While surgery is an established treatment for nonmetastatic UTUC, the role of chemotherapy is still uncertain. Immunotherapy and targeted therapy are showing promising results in the treatment of advanced UTUC. Efforts are being made to uncover the biological and immunological grounds for personalized treatment.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2023)
